DRTS News

Alpha Tau to Participate in Five September Investor Conferences

JERUSALEM, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present and meet investors in the following five investor conferences in September 2025.

August 27, 2025Conferences

Alpha Tau Medical Q1 EPS $(0.12) Beats $(0.13) Estimate

DRTS

May 19, 2025

HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target

DRTS

April 29, 2025

Oramed Pharma Closes Strategic Investment In Alpha Tau Medical; Oramed Affiliate Purchases About 14.1M Alpha Tau's Ordinary Shares $2.612/Shr

DRTS

April 28, 2025

Alpha Tau Granted FDA Approval To Initiate Trial For Patients With Recurrent Glioblastoma

DRTS

April 2, 2025

HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target

DRTS

March 17, 2025

Alpha Tau Receives Medical Device Single Audit Program Certification

DRTS

February 24, 2025

Alpha Tau Medical Q3 EPS $(0.10) Beats $(0.13) Estimate

DRTS

November 20, 2024

HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target

DRTS

May 22, 2024

Alpha Tau Medical Q1 EPS $(0.11) Beats $(0.12) Estimate

DRTS

May 20, 2024

HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target

DRTS

May 16, 2024

Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals Of 2 Landmark Pre-Clinical Studies

DRTS

September 8, 2022